Shares of Eli Lilly LLY rose nearly 2% on Thursday after the company announced that a late-stage study evaluating its experimental once-weekly weight-loss drug, retatrutide, met all primary and key secondary endpoints.

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in 2025.

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic knee pain after 68 weeks

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The company still has a robust business that is delivering excellent results and some upcoming catalysts.

Dec 12 (Reuters) - The European Medicines ‌Agency's ​committee on Friday ‌recommended extending the use of Eli Lilly's ​blockbuster drug Mounjaro for the treatment of type 2 diabetes ‍in adolescents and children ​aged 10 years and above.

Eli Lilly (LLY) said that a late-stage study showed its new injected medication retatrutide helped obese patients lose up to 24% of their body weight in 68 weeks, with an average reduction in knee pain of around 63% at the same dosage level.

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in the development of their GLP-1 therapies.